# Genfine Biotech (Beijing) Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genfine-biotech-beijing-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.genfine.com
- Total disclosed funding: $39M
- Latest round: Series B (Dec 13, 2021)
- Investors on record: 5

## About

Based in Beijing, China and established in 2016, Genfine Biotech (Beijing) Co, Ltd. operates as a biotechnology company which focuses on research, development, manufacturing and distribution of diagnosis products such as diagnosis kit and diagnostic reagents. The company’s founder team has more than ten years of R&D and corporate management experience. At present, the company's headquarters and molecular reagent R&D center are in Beijing. Nanjing is used as an instrument R&D center and molecular enzyme industrialization base. It has a production base of over 20,000 square meters in Changzhou, and has established sales branches in Shanghai and other places.

The company self developed biotechnology platform such as medical sample preservation technology platform, column membrane method nucleic acid extraction reagent platform, magnetic bead material & high-throughput instrument integration platform, Direct qPCR/qRT-PCR detection technology platform, molecular evolution platform, high-density fermentation platform, advanced Protein purification platform.

The company plan to use the series B funding for biotechnology platform construction.

## Funding rounds

- Series B, Dec 13, 2021, $16M — Legend Capital, CMS Asset Management, China Merchants Zhiyuan Capital Investment, Changkejin  Investment
- Series A, Feb 10, 2021, $23M — Hong Shan, Legend Capital

## Investors

- Hong Shan — Series A
- Legend Capital — Series A, Series B
- CMS Asset Management (https://capitalatlas.ai/funds/cms-asset-management) — Series B
- China Merchants Zhiyuan Capital Investment — Series B
- Changkejin  Investment — Series B